Background and Purpose-White matter (WM) ischemic injury, a major neuropathological feature of cerebral small vessel diseases, is an important cause of vascular cognitive impairment in later life. The pathogenesis of demyelination after WM ischemic damage are often accompanied by microglial activation. Fingolimod (FTY720) was approved for the treatment of multiple sclerosis for its immunosuppression property. In this study, we evaluated the neuroprotective potential of FTY720 in a WM ischemia model. Methods-Chronic WM ischemic injury model was induced by bilateral carotid artery stenosis. Cognitive function, WM integrity, microglial activation, and potential pathway involved in microglial polarization were assessed after bilateral carotid artery stenosis. Results-Disruption of WM integrity was characterized by demyelination in the corpus callosum and disorganization of Ranvier nodes using Luxol fast blue staining, immunofluorescence staining, and electron microscopy. In addition, radial maze test demonstrated that working memory performance was decreased at 1-month post-bilateral carotid artery stenosis-induced injury. Interestingly, FTY720 could reduce cognitive decline and ameliorate the disruption of WM integrity. Mechanistically, cerebral hypoperfusion induced microglial activation, production of associated proinflammatory cytokines, and priming of microglial polarization toward the M1 phenotype, whereas FTY720 attenuated microgliamediated neuroinflammation after WM ischemia and promoted oligodendrocytogenesis by shifting microglia toward M2 polarization. FTY720's effect on microglial M2 polarization was largely suppressed by selective signal transducer and activator of transcription 3 (STAT3) blockade in vitro, revealing that FTY720-enabled shift of microglia from M1 to M2 polarization state was possibly mediated by STAT3 signaling. Conclusions-Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion. Visual Overview-An online visual overview is available for this article. 
W hite matter (WM) damage manifests as a core pathology in the progression of various diseases such as stroke, vascular dementia, and multiple sclerosis. 1, 2 Characterized by loss of axon-glial integrity and demyelination, WM injury is an important cause of cognitive deficits after cerebral ischemia and is often associated with microglial activation. 3 A persistent proinflammatory microenvironment after cerebral hypoperfusion is considered an underlying mechanism that hinders remyelination and WM repair. 4 The polarization of microglia has been described as a functional dichotomy: classical (M1, proinflammatory) and alternative (M2, anti-inflammatory) activation. 5 Polarization of microglial populations toward various functional phenotypes can be beneficial or detrimental in response to specific microenvironmental signals after ischemic stroke, which contributes considerably to the regulation of inflammatory status in the injured WM and ultimately impacts the WM integrity. 2, 4, 5 Thus, therapeutic approaches targeting cerebral inflammation should shift from broad suppression of microglia toward the selective balance between their phenotypes in central nervous system repair after chronic injury. Fingolimod (FTY720), a high-affinity agonist of S1P (sphingosine-1-phosphate) receptor, was the first Food and Drug Administration-approved drug for the treatment of relapsing-remitting multiple sclerosis through its immunosuppression effect. 4 Although cause and likewise clinical presentation set the 2 diseases apart, stroke shares certain common downstream mechanisms with multiple sclerosis in WM damage and recovery. 6 Indeed, FTY720 has been used in various models of stroke and neurological disorders. 4, 7 Some small clinical trials showed that oral FTY720 also have therapeutic efficacy in patients with acute stroke, including both ischemic stroke and intracerebral hemorrhage. 8, 9 However, the potential effect of FTY720 on WM ischemic damage is largely unknown. In this study, using a mouse model of WM ischemic damage caused by chronic hypoperfusion, we explored the cellular mechanism of FTY720 in WM injury and repair. Particularly, we focused on whether FTY720 exerted neuroprotective effects through modulating microglial polarization toward M2 type, a potential therapeutic strategy for patients with WM injury.
Materials and Methods
The data that support the findings of this study and analytic methods are available from the corresponding author on reasonable request. The materials are available from commercial sources.
Animals and Bilateral Carotid Artery Stenosis Procedure
All animal studies followed the instructions by the Institute of Animal Care Committee of Tongji Medical College, Huazhong University of Science and Technology, China. A total of 271 wild-type mice were used in the experiment. All the experimental groups were randomized, and all outcome analysis was performed by independent investigators blinded to the treatment condition.
Chronic cerebral hypoperfusion was induced by bilateral carotid artery stenosis (BCAS) as microcoils (0.18 mm internal diameter; Sawane Spring Co, Shizuoka, Japan) were twined around both common carotid arteries as described by Shibata et al.
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Primary Cell Culture
Primary microglia and oligodendrocytes were isolated from the brain of neonatal C57BL/6J mice at P1-P2 as described. 11, 12 For M1 induction, lipopolysaccharide (100 ng/mL, L6529; Sigma-Aldrich) and IFN-γ (interferon-γ; 20 ng/mL; Sigma-Aldrich) were added to the microglial cultures for 24 hours. For M2 induction, IL-4 (interleukin-4; 20 ng/mL) was added to the culture for 24 hours. 5 The study of oligodendrocyte precursor cells (OPCs) apoptosis and differentiation in response to microglia consisted of 6 groups: OPCs were treated with unconditioned OPC culture medium/differentiation medium (OPC) or microglia conditioned medium (CM; in a 1:1 ratio to OPC medium): untreated CM (control), LPS plus IFN-γ-stimulated CM, LPS plus IFN-γ-stimulated and FTY720-treated CM, IL-4-stimulated CM, and LPS plus IFN-γ-stimulated CM added with 100 nmol/L FTY720.
FTY720 Treatment
For FTY720 treatment in vivo, FTY720 (10006292, 0.3 mg/kg; Cayman Chemical Company) was dissolved in PBS and administered intraperitoneally for 3, 10, or 30 consecutive days. For FTY720 treatment in vitro, cells were treated with 100 nmol/L nonphosphorylated FTY720 for 1 hour ahead and then stimulated with LPS and IFN-γ for another 24 hours. The dose and duration of FTY720 was selected based on according to our preliminary experiments and previous studies. [13] [14] [15] Stattic (10 nmol/L) was administered to block signal transducer and activator of transcription 3 (STAT3) pathway. 
Eight-Arm Radial
Statistical Analysis
Statistical analyses were performed using SPSS 19.0. All data were expressed as the mean±SEM except for Luxol fast blue staining, and significance was determined by 2-way 1-way ANOVA with repeated analysis, Mann-Whitney U test, or 1-way ANOVA with Dunnett post hoc test to compare differences between groups. All tests were considered statistically significant at P<0.05.
Results
Cerebral Hypoperfusion-Induced WM Injury and Cognitive Dysfunction Were Partially Reduced by FTY720
Cognitive impairment was detected in mice with cerebral hypoperfusion. 10 Indeed, sham-operated mice quickly improved their performance in the working memory task of the 8-arm radial maze, whereas mice at 1 month after BCAS took significantly more revisiting errors and less different arm choices in the first 8 entries ( Figure 1A ). Interestingly, we found that BCAS mice treated with FTY720 displayed improved performance in both revisiting sessions and different choices count, suggesting an improvement in short-term memory ( Figure 1A ). On the contrary, no spatial reference memory was compromised in this model because there were no significant differences between groups in the reference memory task of the 8-arm radial maze ( Figure 1A) .
In previous studies, working memory deficits have been related either to frontal-subcortical circuits damage or to compromised integrity of hippocampus. 10 To confirm that cognitive decline was a result of the difference in WM lesions in this model, we evaluated the WM lesion grades by Luxol fast blue staining and hippocampus histological changes by Nissl staining at 1 month post-hypoperfusion. We confirmed the disruption of WM integrity by Luxol fast blue stain of the medial part of corpus callosum, caudoputamen, anterior commissure, the internal capsule, and fimbria of hippocampus at 1 month after hypoperfusion. The most severe rarefaction was noted in the medial part of corpus callosum ( Figure 1B and 1D ). In contrast, we found no obvious histological damage in the hippocampus and the cortex in all groups ( Figure 1C and 1D) . Administration of FTY720 mitigated histological damage of WM, which was in agreement with its protective effect on cognitive impairment.
FTY720 Treatment Protected WM Against Chronic Hypoperfusion-Induced Demyelination and Disorganization of Ranvier Nodes
Major components of the WM include neuronal axons, the surrounding myelin sheath, and myelin-producing oligodendrocytes. 3 To further determine which components of WM experienced the heaviest damage and the impact of FTY720, we assessed WM-related markers in corpus callosum using immunofluorescence and Western blot analysis. MAG (myelin-associated glycoprotein), a key myelin protein involved in the maintenance of axon-glial integrity, was compromised at 3 days after BCAS and greatly decreased as hypoperfusion prolonged ( Figure I in the online-only Data Supplement). Whereas, gross myelin marker MBP (myelin basic protein) tended to be lower in BCAS mice, but the difference between the groups did not reach statistical significance, and pan-axon marker neurofilament remained largely unchanged after hypoperfusion ( Figure I in the online-only Data Supplement). Ultrastructural changes of myelination were detected by electron microscopy at 1 month after BCAS. The disruption of myelin was observed as vacuole or grid-liked changes in corpus callosum of mice with BCAS, whereas axons in sham group were intact with well-defined lamellar myelin sheath. The g-ratio in BCAS mice increased significantly, suggesting a reduction in the average myelin thickness, whereas no significant difference in axon diameter or myelinated axon number was observed after hypoperfusion ( Figure IIA in the online-only Data Supplement). After FTY720 treatment, g-ratio was largely reduced approaching the levels seen in sham group. Collectively, the compromised integrity of WM by BCAS was largely attenuated by FTY720 treatment, both in MAG expression and in the ultrastructure (Figures I and IIA in the online-only Data Supplement), indicating FTY720's protective effect on myelin status.
To further determine whether myelin stability is paralleled by alterations in oligodendrocyte myelination, we characterized the proliferation and differentiation of OPCs by bromodeoxyuridine (BrdU) labeling at 1 month posthypoperfusion. Both Figure IIB in the online-only Data Supplement). Therefore, FTY720 might reverse WM ischemic injury by its protective effects via induction of oligodendrocyte proliferation and differentiation.
The structural organization of nodes of Ranvier is vulnerable to ischemia and is a sensitive indicator of WM ischemic injury. 3, 16 To test the integrity of the paranodal septate-like junctions and the nodal regions, we analyzed 3 key proteins (Caspr [contactin associated protein], voltage-gated sodium channel, and panNeurofascin) of nodes of Ranvier at 1 month after BCAS. We found a significant reduction of colocalization of Caspr and panNeurofascin within the paranodes after chronic hypoperfusion, and FTY720 treatment profoundly reversed this reduction (Figure 2A) . And there was a significant increase in the length of the voltage-gated sodium channel domain after hypoperfusion, indicating the injured status of Ranvier nodes. In FTY720-treated group, the damage of nodes was largely reversed ( Figure 2B ). Meanwhile, no difference in node number was detected between groups ( Figure 2B ). Together, our data suggest that FTY720 exerts its protective effect against structural derangement at the nodes of Ranvier after hypoperfusion.
FTY720 Attenuated Neuroinflammation After WM Ischemic Injury via Altering Microglial Polarization
Microglial activation with enhanced release of inflammatory mediators is known to impair myelination in different models of WM injury. [2] [3] [4] Here, we found the number of cells positive for the general marker ionized calcium-binding adapter molecule 1 (Iba-1) and the phagocytosis marker CD68 (cluster of differentiation 68) were remarkably elevated in BCAS mice, reached the peak on the 10th day after BCAS, and then sustained the status of highly activated (Figure 3 ). Microglia were significantly activated after prolonged hypoperfusion in the higher magnification, characterized by hypertrophic morphology, with thickened and retracted processes. In contrast, FTY720-treated mice showed fewer Iba-1 + or CD68
+ microglia displaying smaller cell bodies and thinner processes after hypoperfusion (Figure 3 ), indicating that FTY720 may attenuate neuroinflammation by suppressing microglial activation.
Activated microglia exist along a continuum of 2 functional states of polarization, namely, M1-type (classical/ proinflammatory activation) and M2-type (alternative/antiinflammatory activation). Microglia with M1 phenotype are characterized by upregulation of CD16 Fc receptors, CD32, CD86, IL (interleukin)-1β, IL-23, TNF (tumor necrosis factor)-α, and iNOS (inducible nitric oxide synthase), whereas microglia of M2 phenotype display the upregulation of arginase (Arg)-1, mannose receptor (CD206), IL-10, TGF (transforming growth factor)-β, and Ym-1 (chitinase 3-like 3). We explored the phenotype of microglia in WM ischemic injury by double labeling Iba-1 with M1 marker CD16/32 and M2 marker CD206. With prolonged hypoperfusion, the number of CD16/32 + Iba-1 + cells (M1) was substantially increased, whereas CD206 + Iba-1 + cells (M2) were significantly decreased compared with sham-operated mice ( Figure 4A and 4B) . It was interesting that the number of M2-type cells remained almost unchanged in FTY720-treated mice, whereas the M2:M1 ratio was significantly upregulated in FTY720-treated mice compared with vehicle-treated group ( Figure 4A and 4B) , indicating that FTY720 switched microglia polarization from M1 to M2 type in WM ischemic injury. To further distinguish this differential polarization from simply suppressing microglia, CD11b-high microglia were isolated from WM 10 days or 1 month after surgery and analyzed by fluorescence-activated cell sorting. The populations of cells positive for M1 markers CD16/32 or CD86 in microglia were significantly increased, whereas CD206-or CD23-positive cells in microglia slightly decreased compared with sham-operated control ( Figure 4C and 4D). After FTY720 treatment, this imbalance of microglia polarization was diminished, as CD16/32 + or CD86 + M1 cells ameliorated and CD206
+ or CD23 + M2 cells elevated ( Figure 4C and 4D) . Together, our results consistently
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indicated that FTY720 not only prevented the activation of microglia subsequent to BCAS but also intensified its protective effects through modulating microglia polarization toward M2 type.
To further investigate whether FTY720 regulated microglial polarization directly, we used primary cultured microglia, induced M1/M2 polarization by LPS plus IFN-γ or IL-4 stimulation in vitro, and then measured the expression of various M1/M2 markers under different treatment. Quantitative real-time polymerase chain reaction revealed that M1 markers (CD86, TNF-α, iNOS, CD32, and IL-1β) were significantly increased by LPS plus IFN-γ stimulation, and M2 markers (TGF-β, Arg-1, and Ym-1) were greatly suppressed, although several M2 markers (CD206 and IL-10) decreased without significance ( Figure 5A ). These alterations in M1 and M2 markers were significantly attenuated by FTY720 treatment ( Figure 5A ). Consistently, Western blot results showed similar alterations at protein level as M1 markers (iNOS and CD16/32) increased and M2 markers (arginase-1 and CD206) decreased by LPS plus IFN-γ stimulation ( Figure 5B ). FTY720 treatment attenuated these alterations significantly, indicating its direct modulation in microglial polarization ( Figure 5B ).
FTY720 Modulated Oligogenesis and OPCs Maturation via M1 to M2 Switch of Microglia
The above findings raised the questions about the possible relevance of microglial polarization with oligogenesis and myelination after WM ischemic injury. To directly address this question, we sought to determine the response of OPCs using microglia CM. First, cytokines IL-1β, IL-13, TNF-α, and TGF-β in CM by different stimulation and treatment were analyzed by ELISA. LPS plus IFN-γ stimulation profoundly increased the levels of proinflammatory proteins (IL-1β and TNF-α) and downregulated anti-inflammatory proteins (IL-13 and TGF-β; Figure 6A ). FTY720 treatment attenuated these alterations ( Figure 6A ), which was consistent with its protective effect on microglial polarization. Next, primary cultured OPCs were incubated with CM from the different treatment groups for 3 days. TUNEL assay showed that inflammatory stimulus led to OPCs apoptosis with increased TUNEL + Olig2 + cells, which was significantly reversed in FTY720-treated CM (Figure 6B and 6C) . In addition to the increase of oligodendrocyte survival, FTY720 restored oligodendrocyte 
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December 2017 differentiation as demonstrated by an increased number of MBP + differentiated oligodendrocytes in FTY720-treated CM ( Figure 6B and 6C) . To exclude the possibility of FTY720's direct effect on OPCs, we set a separate group as LPS plus IFN-γ-stimulated CM added with 100 nmol/L FTY720. Quantification of TUNEL + OPCs showed that FTY720's direct protection on OPCs reduced a few apoptotic cells but not as good as FTY720-treated CM did ( Figure 6B and 6C) . And myelinating oligodendrocytes also revealed no significant differences with additional 100 nmol/L FTY720 in CM ( Figure 6B and 6C) , suggesting that the protective effect of FTY720 was likely attributed to its modulation on microglia polarization instead of the direct effect on OPCs.
FTY720 Facilitated M1 to M2 Switch of Microglia via STAT3 Pathway
To further elucidate which signaling pathways were involved, we performed quantitative real-time polymerase chain reaction to screen various related markers (interferon regulatory factor 3, interferon regulatory factor 4, msh homeobox 3, peroxisome proliferator-activated receptor gamma, STAT3, STAT6, JAK [janus kinase]1, JAK2, and JAK3) that have 
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December 2017 been previously reported. 17 Compared with LPS plus IFN-γ stimulation, IL-4 incubation induced enhanced activation of PPAR-γ, STAT3, STAT6, and JAK3 ( Figure III in the online-only Data Supplement). Treatment of FTY720 upregulated the mRNA levels of STAT3, which was increased over 2-folds compared with LPS plus IFN-γ group ( Figure III in the online-only Data Supplement). Western blot further confirmed that the total protein expression and phosphorylation level of STAT3 were enhanced with FTY720 treatment, both in vivo and in vitro ( Figure 5B and 5C ). To seek deeper insight into the underlying role of STAT3 pathway in this situation, Stattic, reported previously to highly and selectively block STAT3 pathway, 18 was chosen to inhibit activation of STAT3. We found that FTY720's effect on microglia M2 polarization was diminished after STAT3 activity was inhibited by Stattic (10 nmol/L; Figure 5B ). Therefore, these results indicated that FTY720 was likely to shift microglia from M1 to M2 polarization state via STAT3 activation.
Discussion
Demyelination profoundly compromise the communication between brain regions and is thought to underlie long-term cognitive deficits in central nervous system disorders such as stroke and multiple sclerosis. 6 The present study showed that FTY720 significantly attenuated myelin loss, protected nodal structures, promoted OPCs proliferation and maturation, and finally facilitated myelin-axon integrity in the WM after BCAS, paralleled by an improvement in working memory performance. The underlying mechanisms for neuroprotection by FTY720 were probably attributed to STAT3-mediated modulation of microglia toward M2 polarization. To the best of our knowledge, this study is the first to indicate a protective effect and the underlining mechanism of FTY720 in hypoperfusion-induced WM injury.
Previous studies suggested benefits of FTY720 in multiple sclerosis model through immunosuppression and direct protection on OPCs via S1P signaling.
19 FTY720 was also reported to reduce oxidative stress, microglia activation, and associated proinflammatory cytokine expression in central nervous system injury. 12, 20 To further illustrate whether FTY720 exerts its protective effects on demyelination directly or not, we separately treated OPCs with CM from activated microglia. FTY720 significantly mitigated inflammation-induced OPCs apoptosis and promoted oligodendrocyte differentiation, but this phenomenon could not be duplicated by simply adding FTY720 to OPCs CM. In vivo, FTY720 could largely attenuate microglial activation, downregulate the production of proinflammatory cytokines, and promote OPCs proliferation and differentiation after BCAS. Our findings strongly suggested that FTY720's efficacy on WM ischemic injury was likely attributed to modulation of OPCs survival microenvironment mediated by microglial inflammatory/anti-inflammatory balance state.
It has been demonstrated that the neuroinflammation response can contribute to the pathogenesis of ischemic stroke. 2, 4, 8, 21 M2-type microglia have been reported to be an essential part of the regenerative response in central nervous system demyelinating diseases by promoting oligodendrocyte differentiation. 22 We observed that prolonged cerebral hypoperfusion significantly induced microglia activation in preferentially M1 polarization state after BCAS. A switch from M1 to M2 polarization was stably detected after FTY720 treatment both in vivo and in vitro. Our in vitro data further illustrated that FTY720 could significantly ameliorate inflammatory microenvironment and promote repair of the injured oligodendrocytes. Therefore, these results further determined that FTY720's direct modulation on microglia polarization, rather than general immunosuppressive effects, would be an important pathway involved in its efficacy on WM injury.
To date, how FTY720 modulates microglia toward M2 polarization remains uncharacterized. We screened several possible signaling pathways crucial for microglial M1/M2 polarization and found the obvious activation of STAT3 pathway in FTY720 treatment group. Our results demonstrated that FTY720 significantly increased both the expression and phosphorylation level of STAT3 compared with vehicle group. Consistently, previous in vitro data suggested that S1P could activate JNK/STAT3 signaling cascades, 23 which were associated with M2 polarization. 17 In addition, FTY720-induced anti-inflammatory effects and polarization toward M2-type microglia were abolished by the STAT3 inhibitor, Stattic. The effect of Stattic on different STAT family members was reported to be temperature dependent and highly selective for STAT3 at 37°C, shown to inhibit cellular phosphorylation of STAT3 with little effect toward STAT1 phosphorylation or the phosphorylation of JAK1, JAK2, and c-Src (proto-oncogene tyrosine-protein kinase). 18 In spite of the possible lack of selectivity of FTY720 and Stattic, these results further illustrated that FTY720 manipulated microglia polarization after WM ischemic injury via STAT3 pathways.
There were several limitations of our study, which may preclude the generalizability of our findings in human WM diseases. The murine BCAS model used in this study replicates some of the key features of ischemic WM injury, including WM pathology and cognitive decline, whereas other aspects of the disease, such as an underlying vascular pathology triggered by hypertension or diabetes mellitus and variability of age and sex, are lacking. Nonetheless, the postmortem brain pathology of WM disease patients shares many features with the anatomic pathology noted in post-BCAS mice, including both microglia activation as well as frank demyelination. 24, 25 Therefore, our data suggested that FTY720 might exhibit a potential of clinical application in WM ischemic injury. Although we intended to identify the specific mechanism of FTY720's protection on WM, the diverse subtypes of S1P receptors expressed on peripheral immune cells and brain-intrinsic cells preclude a better understanding of targeted cell types responsible for the mechanisms of FTY720. 19 Recent works in human cerebral ischemia have demonstrated that FTY720 restrains lymphocytes within the lymphoid organs resulting in reduced circulating lymphocyte counts. 8, 26 However, in neonatal hyperoxia, it has been proved that brain lymphocyte counts were modulated neither by FTY720 nor by hyperoxia. 12 In the current study, we cannot exclude the possibility of peripheral immune cells and various brain-intrinsic cells involvement in protective effect of FTY720 after chronic cerebral hypoperfusion. In addition, we could not rule out
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whether the drug has direct effects on spatial learning and memory. Further pharmacological investigation of FTY720 on cognitive function is needed in the future. Nevertheless, our results demonstrate that FTY720 directly modulated microglia/macrophages-mediated immune-inflammatory state toward better microenvironment facilitated for myelin repair and regeneration in WM ischemic injury.
In conclusion, FTY720 has shown its neuroprotective effect in multiple sclerosis and acute stroke. 4 The present study further proved its potential efficacy in preventing WM ischemic injury induced by chronic hypoperfusion model. Accordingly, we think that the strategy of FTY720 treatment in patients with chronic cerebral hypoperfusion is promising and worth further evaluation.
